2 results match your criteria: "Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA.[Affiliation]"
Article Synopsis
- Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a group of blood diseases where the bone marrow doesn’t make blood cells properly, leading to problems like low blood cell counts and overproduction of certain cells.
- Recent research has helped scientists understand the genetic changes that happen in these diseases, such as specific chromosome issues and mutations that affect how blood cells grow.
- Different types of MDS/MPN have their own unique genetic features, and knowing these can help doctors predict how serious the disease might be and improve treatment for patients.
Chimeric antigen receptor (CAR) T-cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times. As the clinical use has progressed rather rapidly since the first approval in 2017, toxicities beyond cytokine release syndrome and immune effector cell-associated neurological syndrome have surfaced. Cytopenias are common in <30 days ("early"), 30-90 days ("short-term") as well as >90 days ("prolonged"); and have clinical implications to patient care as well as resource utilization.
View Article and Find Full Text PDF